Welcome to our dedicated page for Gossamer Bio news (Ticker: GOSS), a resource for investors and traders seeking the latest updates and insights on Gossamer Bio stock.
Company Overview
Gossamer Bio, Inc is a clinical-stage biopharmaceutical company engaged in the discovery, acquisition, development, and commercialization of novel therapeutic candidates. The company is strategically positioned in the fields of immunology, inflammation, and oncology, utilizing an asset-rich in-licensing model that leverages the deep experience of its founding team. This approach focuses on targeting high unmet needs among patient populations with conditions that are complex and challenging to manage, ensuring that Gossamer Bio remains relevant in addressing critical healthcare issues.
Core Business Areas
The company’s operations are centered on identifying and advancing therapeutic candidates that address key disease mechanisms such as cellular overgrowth, fibrosis, and dysregulated vascular remodeling. By focusing on immunology, inflammation, and oncology, Gossamer Bio develops treatments aimed at conditions including pulmonary arterial hypertension, inflammatory bowel diseases like ulcerative colitis and Crohn’s disease, specific oncology indications, and moderate-to-severe respiratory conditions such as eosinophilic asthma. Its expert research and development team capitalizes on proven methodologies in drug discovery, ensuring that each candidate is backed by comprehensive preclinical and clinical evaluation.
Gossamer Bio (Nasdaq: GOSS) announced it will report its Q2 2021 financial results on August 9, 2021. The live conference call will take place at 4:30 p.m. ET, where management will discuss the results and provide a corporate update. Investors can join the call via domestic at (833) 646-0603 or international at (929) 517-9782. A replay will be available for 30 days on their website, www.gossamerbio.com. Gossamer is focused on developing therapeutics in immunology, inflammation, and oncology.
Gossamer Bio (Nasdaq: GOSS) announced its participation in the 2021 Virtual Congress of the European Crohn’s and Colitis Organisation (ECCO), taking place from July 2-3 and 8-10. On July 8, William Sandborn, M.D., will present findings from the completed Phase 1b clinical trial for GB004, an oral gut-target HIF-1α stabilizer, focusing on target engagement and pharmacodynamic biomarkers in patients with mild-to-moderate ulcerative colitis. The presentation and poster will later be accessible on Gossamer Bio's website.
Gossamer Bio, Inc. (Nasdaq: GOSS) has announced the promotion of Richard Aranda, M.D., to Chief Medical Officer. Dr. Aranda, who has been with Gossamer since February 2018, previously served as Senior Vice President and Head of Clinical Development. His leadership is seen as crucial for the company's success in drug development, having extensive experience in clinical roles at Receptos and Novo-Nordisk. Gossamer Bio focuses on developing therapeutics in immunology, inflammation, and oncology, aiming to enhance patient care in these areas.
Gossamer Bio (Nasdaq: GOSS) has announced the appointment of Dr. Sandra Milligan to its Board of Directors. Dr. Milligan brings extensive experience from her role as Head of Research and Development at Organon, and previous positions at Merck and Genentech. CEO Faheem Hasnain praised her knowledge as invaluable for Gossamer’s mission to develop novel therapies in immunology, inflammation, and oncology. With a strong educational background in biology, psychology, medicine, and law, Dr. Milligan is expected to contribute significantly to the company's strategic direction.
Gossamer Bio, Inc. (Nasdaq: GOSS) reported its Q1 2021 financial results, noting a net loss of $57.6 million or $0.78 per share, compared to a net loss of $54.1 million or $0.87 per share in Q1 2020. Cash and equivalents stood at $453.3 million, sufficient to fund operations into 2023. Key clinical updates include ongoing trials for seralutinib in pulmonary arterial hypertension, GB004 for inflammatory bowel disease, and GB1275 for solid tumors, with results expected in 2022. The company also announced leadership promotions.
Gossamer Bio, Inc. (GOSS) announced that Chief Scientific Officer Luisa Salter-Cid will resign effective April 30, 2021. Laura Carter, previously Senior Vice President of Research & Translational Biology, will succeed her. Chairman and CEO Faheem Hasnain acknowledged Salter-Cid's contributions in developing the pre-clinical pipeline and welcomed Carter, highlighting her extensive experience in immunology and clinical development. Carter's background includes leadership roles in various biopharmaceutical firms, enhancing her capability to drive Gossamer’s clinical programs forward.
Gossamer Bio (Nasdaq: GOSS) has promoted Caryn Peterson to Executive Vice President, Regulatory Affairs, effective immediately. In her new role, Peterson will lead the company's regulatory and quality functions and develop global regulatory strategies for clinical and pre-clinical programs. She has been with Gossamer since 2018, previously serving as Senior Vice President, Regulatory & Quality. CEO Faheem Hasnain highlighted her strategic acumen and strong relationships with regulatory agencies as vital for advancing Gossamer's clinical portfolio, which includes candidates like seralutinib and GB004.
Gossamer Bio, Inc. (Nasdaq: GOSS) reported its financial results for Q4 and the full year 2020, reflecting a net loss of $64.6 million for the quarter and $243.4 million for the year. R&D expenses for Q4 were $38.9 million, down from $42.6 million in 2019, while full-year R&D expenses increased to $160.9 million. The company has $512.6 million in cash and equivalents, expected to fund operations into 2023. Notable clinical trials include seralutinib for PAH and GB004 for IBD, with data expected in 2022.
Gossamer Bio, a clinical-stage biopharmaceutical company (Nasdaq: GOSS), announced it will report its fourth quarter and full-year 2020 financial results on February 25, 2021. A conference call and webcast will follow at 8:30 a.m. ET that same day, providing an update on the financial results and corporate developments. Investors can access the live webcast via the company's website. Gossamer Bio is dedicated to developing therapeutics in immunology, inflammation, and oncology, aiming to become a leader in these fields.
Gossamer Bio, a clinical-stage biopharmaceutical company (Nasdaq: GOSS), has announced a conference call and webcast on February 18, 2021, at 11:00 am ET. The event will discuss GB004, their oral HIF-1α stabilizer aimed at treating inflammatory bowel disease (IBD), specifically ulcerative colitis (UC). Esteemed experts in the field, including William Sandborn, Silvio Danese, and Cormac Taylor, will join Gossamer management for insights and a Q&A session. The webcast will be available on the company's website, and a replay will be accessible for 30 days.
FAQ
What is the current stock price of Gossamer Bio (GOSS)?
What is the market cap of Gossamer Bio (GOSS)?
What is Gossamer Bio's core business focus?
How does Gossamer Bio generate revenue?
What therapeutic areas does the company target?
How does the company differentiate itself from competitors?
What is the significance of focusing on high unmet needs?
What role does the company’s clinical-stage status play in its operations?
